Drug intelligence / Profile preview

AIP-307

Development stage: Preclinical
Lead developer: AIP
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

AIP-307 is a diagnostic radiopharmaceutical candidate under development by Advanced Innovative Partners (AIP) for the detection and imaging of Glioblastoma Multiforme (GBM). As a diagnostic agent, it is designed to utilize a radioactive isotope coupled with a targeting moiety to visualize tumor cells or specific biomarkers associated with high-grade gliomas through nuclear imaging techniques such as PET or SPECT. This precision imaging approach aims to assist in the diagnosis, staging, and monitoring of GBM. The program is currently in the IND-enabling phase, preparing for clinical trial applications.

Other names: AIP-307-AIP-radiopharmaceutical-Glioblastoma Multiforme (Diagnostic)

Beyond the preview

Go deeper on AIP-307.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIP-307.

Explore the full profile